In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines Steven J. WolfLaurence P. G. WakelinDaniel R. Catchpoole Original Article 10 March 2009 Pages: 1059 - 1069
A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma Takaki YoshikawaAkira TsuburayaJunichi Sakamoto Original Article 13 March 2009 Pages: 1071 - 1077
Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium Yoshiaki YamadaYouko ItohNobuaki Honda Original Article 11 March 2009 Pages: 1079 - 1083
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy Alain G. MusendeAndy EberdingEmma Tomlinson Guns Original Article 20 March 2009 Pages: 1085 - 1095
Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells Xiao-Li LiChong-Zhi WangChun-Su Yuan Original Article 11 March 2009 Pages: 1097 - 1104
Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974 Karen Y. WondersDavid S. HydockReid Hayward Original Article 08 April 2009 Pages: 1105 - 1113
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells Maiko SuzukiManabu EndoHidemi Rikiishi Original Article 11 March 2009 Pages: 1115 - 1122
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure Zheng-Tao ZhouXin-Hua XuCai-Hong Wen Original Article 26 March 2009 Pages: 1123 - 1127
Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro Yasuhiko KanoMasaru TanakaYusuke Furukawa Original Article 22 March 2009 Pages: 1129 - 1137
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer Olivier RixeSandra X. FrancoHope S. Rugo Original Article 18 March 2009 Pages: 1139 - 1148
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study Stephen I. ShibataJames H. DoroshowEdward M. Newman Original Article 26 March 2009 Pages: 1149 - 1155
Antineoplastic activity of idazoxan hydrochloride G. F. EilonL. WeisenthalL. M. Slater Original Article Open access 24 March 2009 Pages: 1157 - 1163
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors Noboru YamamotoTomohide TamuraEisei Shin Original Article 24 March 2009 Pages: 1165 - 1172
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer Hui-Ju Ch’angChin-Lun HuangLi-Tzong Chen Original Article 25 March 2009 Pages: 1173 - 1179
A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer Yoshitaka TotaniYuji SaitoHiroki Sakakibara Original Article 18 April 2009 Pages: 1181 - 1185
Expression of Na,K-ATPase-β1 subunit increases uptake and sensitizes carcinoma cells to oxaliplatin Ramakumar TummalaDaniel WolleLakshmi Pendyala Original Article Open access 26 March 2009 Pages: 1187 - 1194
Thymidylate synthetase allelic imbalance in clear cell renal carcinoma Davide ColavitoGiuseppe CarteiAlberta Leon Original Article 22 March 2009 Pages: 1195 - 1200
Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn Anna IsrayelyanEdward John ShannonKonstantin G. Kousoulas Original Article 24 March 2009 Pages: 1201 - 1210
Experimental study of combination therapy with S-1 against pancreatic cancer Jun YoshizawaAsako TakizawaYoshinori Yamada Original Article 01 April 2009 Pages: 1211 - 1219
Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1α in Ehrlich ascites tumor cells Akhilesh KumarSaritha S. D’SouzaK. M. Lokanatha Rai Original Article 16 April 2009 Pages: 1221 - 1233
Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition Giampietro ViolaLaura CecconetGirolamo Cirrincione Original Article 11 April 2009 Pages: 1235 - 1251
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma Michele ReniS. CeredaE. Villa Original Article 21 April 2009 Pages: 1253 - 1259
Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice Timothy H. MarczyloDarren CookeAndreas J. Gescher Original Article 11 April 2009 Pages: 1261 - 1268